An Open-Label Phase IV Study of the Efficacy of Bortezomib-based Combination Therapy the Treatment of Subjects With Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone; Doxorubicin; Thalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 03 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
- 03 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Apr 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.